JPMorgan Downgrades ChemoCentryx (CCXI) to Neutral

JPMorgan analyst Anupam Rama downgraded ChemoCentryx (NASDAQ: CCXI) from Overweight to Neutral with a price target of $15.00 (from $14.00).

The analyst steps the sidelines given anticipation for continued progress coupled with a range-bound stock valuation over the NT due to a lack of catalysts.

For an analyst ratings summary and ratings history on ChemoCentryx click here. For more ratings news on ChemoCentryx click here.

Shares of ChemoCentryx closed at $12.67 yesterday.

You May Also Be Interested In

• Keurig Dr Pepper (KDP) PT Raised to $39 at Jefferies
• Acrivon Therapeutics Inc (ACRV) PT Lowered to $22 at Jones Trading
• Jefferies Downgrades Calix (CALX) to Hold